PMID- 24687427
OWN - NLM
STAT- MEDLINE
DCOM- 20150713
LR  - 20221207
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Linking)
VI  - 30
IP  - 8
DP  - 2014 Nov
TI  - Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for 
      glycaemic control with body weight benefits in type 2 diabetes.
PG  - 742-8
LID - 10.1002/dmrr.2548 [doi]
AB  - BACKGROUND: Achieving recommended glycated haemoglobin (HbA1c ) targets in 
      patients with type 2 diabetes mellitus (T2DM) requires effective control of 
      fasting and post-prandial plasma glucose. As T2DM progresses, oral anti-diabetics 
      are no longer sufficient to maintain glycaemic control. Five phase III studies in 
      the GetGoal clinical trial programme assessed the efficacy of lixisenatide, a 
      once-daily prandial glucagon-like peptide-1 receptor agonist, in combination with 
      oral anti-diabetics in patients with T2DM insufficiently controlled using oral 
      anti-diabetics. METHODS: A meta-analysis was performed of the results of five 
      24-week clinical trials (comprising 2760 patients) concerning lixisenatide or 
      placebo plus oral anti-diabetic therapy. The primary endpoint of these studies 
      was change in HbA1c at week 24. Changes in fasting and post-prandial plasma 
      glucose, and weight were also established as were the odds ratios for 
      hypoglycaemia and composite safety and efficacy endpoints. Meta-analysis outcomes 
      were assessed using a random effects model. All meta-analyses were performed 
      using RevMan, version 5.1. RESULTS: Lixisenatide was significantly better than 
      placebo in terms of achieving all endpoints in this meta-analysis, including the 
      primary endpoint change in HbA1c at week 24, with p < 0.0001 for all endpoints. 
      The mean number of symptomatic hypoglycaemic events per patient year was 
      increased for patients in the lixisenatide versus placebo groups (p = 0.04). 
      However, compared with patients in the placebo group, patients treated with 
      lixisenatide were more likely to achieve composite efficacy and safety endpoints. 
      CONCLUSIONS: This meta-analysis demonstrates that lixisenatide in combination 
      with oral anti-diabetic therapy significantly improves outcomes combining 
      efficacy and safety parameters in patients with T2DM.
CI  - (c) 2014 The Authors. Diabetes/Metabolism Research and Reviews published by John 
      Wiley & Sons, Ltd.
FAU - Raccah, Denis
AU  - Raccah D
AD  - Department of Diabetology, University Hospital Sainte-Marguerite, Marseille, 
      France.
FAU - Gourdy, Pierre
AU  - Gourdy P
FAU - Sagnard, Luc
AU  - Sagnard L
FAU - Ceriello, Antonio
AU  - Ceriello A
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
RN  - 0 (GLP1R protein, human)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Peptides)
RN  - 0 (Receptors, Glucagon)
RN  - 0 (Sulfonylurea Compounds)
RN  - 0 (Thiazolidinediones)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 74O62BB01U (lixisenatide)
RN  - 9100L32L2N (Metformin)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Administration, Oral
MH  - Clinical Trials, Phase III as Topic
MH  - Combined Modality Therapy/adverse effects
MH  - Diabetes Mellitus, Type 2/blood/complications/*drug therapy/metabolism
MH  - Drug Administration Schedule
MH  - *Drug Resistance, Multiple
MH  - Drug Therapy, Combination/adverse effects
MH  - Glucagon-Like Peptide-1 Receptor
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hyperglycemia/*prevention & control
MH  - Hypoglycemia/chemically induced
MH  - Hypoglycemic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Metformin/administration & dosage/adverse effects/therapeutic use
MH  - Multicenter Studies as Topic
MH  - Overweight/chemically induced/complications/*prevention & control
MH  - Peptides/administration & dosage/adverse effects/*therapeutic use
MH  - Pioglitazone
MH  - Randomized Controlled Trials as Topic
MH  - Receptors, Glucagon/*agonists/metabolism
MH  - Sulfonylurea Compounds/administration & dosage/adverse effects/therapeutic use
MH  - Thiazolidinediones/administration & dosage/adverse effects/therapeutic use
OTO - NOTNLM
OT  - glycaemic control
OT  - lixisenatide
OT  - oral anti-diabetics
OT  - prandial
OT  - type 2 diabetes mellitus
EDAT- 2014/04/02 06:00
MHDA- 2015/07/15 06:00
CRDT- 2014/04/02 06:00
PHST- 2013/12/27 00:00 [received]
PHST- 2014/02/18 00:00 [revised]
PHST- 2014/03/19 00:00 [accepted]
PHST- 2014/04/02 06:00 [entrez]
PHST- 2014/04/02 06:00 [pubmed]
PHST- 2015/07/15 06:00 [medline]
AID - 10.1002/dmrr.2548 [doi]
PST - ppublish
SO  - Diabetes Metab Res Rev. 2014 Nov;30(8):742-8. doi: 10.1002/dmrr.2548.